Latest Pharma & Healthcare Insights

Study Concedes Racial, Socioeconomic inequality in Genomic Testing in Early Breast Cancer

Company Report

 Race and socioeconomics emerge to be key aspects in both the usage of genomic testing and how the test outcomes monitor physician’s treatment choices in early-stage breast cancer patients, as per a new study.

Scientists from the University of Colorado, Aurora, inspected more than 140,000 patient evidence and found that Medicaid and Medicare patients, African-American patients and those treated at community centres were notably less likely to be approved with Genomic Health's Oncotype DX assay, which avails the expression of 21 genes to anticipate chemotherapy benefit and breast cancer reoccurrence. 

In addition, the team detected that younger African-Americans who accepted testing were more prone than other groups to obtain chemotherapy even when their test scores suggested against such treatment. 

While African-Americans were less inclined to seize testing with Oncotype DX, those who did were more attainable to be tested even when they did not reconciled the National Comprehensive Cancer Network recommendations for such testing. 

Also, Factors adding to the likelihood of RS testing constituted treatment at higher tumour grade, community facilities, and being male. Marginally superior odds were also ascertained for recipient of governmental health insurance correlated with those who have private health allowance. 

In addition, the UC Aurora group created that junior black patients and patients with community facilities were more liable to receive chemotherapy even if they had stunted assay scores. Patients with private insurance were also more likely to receive chemotherapy than those on government assistance. 

We show that doctors are positively using this test to decide who receives chemotherapy along with their treatment. In fact, of all the variables were analysed, and test was most strongly related with the chance that a patient goes on to receive chemotherapy.

According to Pharmaion, pharma and healthcare consultants recent report, United States Breast Cancer Diagnostic Devices Market Opportunities, 2010 - 2020” analyses that despite, their study does have certain constraints, inclusive of its lack of data on patients, the factors lumped together with the use and overuse of the test may be different, which is  attributed to a better accessibility, wider availability and high acceptance rates of the test by oncologists.


Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News